Oncology

A groundbreaking trial testing if a coffee infused with an ancient herb can slow prostate cancer recurrence is nearing completion, offering hope for a new era.

New York Medicaid now funds a vital therapy to prevent chemo-induced hair loss, breaking down financial barriers for low-income cancer patients.

Boston's Bio-IT World conference shifts from AI theory to execution, showcasing how the life sciences industry is now deploying AI to accelerate new therapies.

With a multi-billion dollar track record of IPOs and acquisitions, the veteran CEO's appointment signals Frazier's focus on navigating complex markets.

New preclinical data for ATNM-400 and Actimab-A shows promise for treating resistant solid tumors and AML, highlighting a new frontier in cancer therapy.

Clinical AI launches MAIA™ on Google Cloud Marketplace, using Gemini AI to solve the patient enrollment crisis that stalls 80% of medical studies.

Preclinical data suggests an investigational drug can shift burn wounds from a state of chronic inflammation toward active regeneration and repair.

With FDA clearance for clinical trials, CanWell Pharma’s novel CAN016 ADC brings a two-pronged attack against drug-resistant HER2-positive cancers.

Expanded Medicare payment for RefleXion's SCINTIX therapy removes major financial hurdles, opening doors for advanced cancer care in community centers.

Delcath Systems is set to showcase its innovative HEPZATO KIT at SIR 2026, signaling growing adoption and a pivotal moment for its targeted cancer therapy.

Biotech veteran Dr. Vince O'Neill joins Mosaic Therapeutics to spearhead its synergistic precision oncology pipeline, aiming to transform cancer treatment.

A stark new benchmark study reveals poor survival in late-stage GvHD, just as MaaT Pharma’s microbiome therapy shows dramatically better outcomes.

The Our Health Our Wellness campaign aims to close critical health disparity gaps with resources, events, and education for underserved communities.

Facing a severe cash crunch and delisting threats, the biotech firm is halting development and seeking buyers for its innovative cancer drug pipeline.

A novel drug aims to break down resistance in hard-to-treat lung and bile duct cancers, with key data set for a major oncology conference.

The Polish biotech will showcase its STRIDE® platform at AACR 2026, promising more precise ways to measure cancer's response to therapy.

A new, imageable liver cancer therapy is one step closer to patients, thanks to a strategic partnership securing a vital US-based medical isotope supply.

Final trial data shows pralsetinib offers years of survival for RET+ lung cancer, but realizing its full potential hinges on overcoming diagnostic hurdles.

A new, highly selective oral drug for the most common form of dwarfism has been cleared for U.S. trials, offering hope for a more convenient treatment.

Formerly Asha Therapeutics, the biotech rebrands with top talent and an AI platform that designs novel medicines from scratch for humanity's toughest diseases.